life scienc tool diagnost
outperform neutral
price month
 close
downgrad neutral deal
move neutral propos acquisit downgrad petx
neutral outperform follow elanco neutral propos
acquisit compani lower target price
revenu estim expect success deal
complet ascrib valu per share
cash conting valu right relat achiev entyc
sale mileston
detail petx deal strengthen elan foothold companion
anim market sale ad entyc appetit simul dog
nocita post-op pain dog cat portfolio importantli
exist econom relat gallipr collabor alreadi
favor deal elimin futur royalti expens estimate
gross sale mileston payment two outstand sale build
leverag elan global size scale
reinforc elan stand-alone evolut addit petx current
commerci product jumpstart effort creat
diversifi portfolio
faster-grow higher-margin product
bolster develop pipelin target could meaning
opportun area atop dermat addit presum
effort therapeut categori addit view synergi
forc
infrastructur acceler traction entyc million sale
nocita million latter support new dedic specialti
sale effort still focu remain elan underli margin expans
expect massiv bp ramp ebitda margin
next five year continu execut cost structur effici
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
petx companion anim therapeut compani focus
licens develop commerci biopharmaceut
product companion anim
price apr rate outperform neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
grey sky scenario assum lower peak sale
key product current model meaning
contribut addit product develop well
potenti liquid profit issu
 close
blue sky scenario base expect
success complet elanco acquisit petx
april elanco announc acquir aratana stock-for-stock
transact aratana share exchang share elanco
conting valu right cvr worth entyc gener million sale juli
decemb million sale juli
base april close price deal valu premium
close account cvr repres maximum potenti transact
valu million equat p/sale multipl transact
expect close late
upon deal close recogn incom us purpos
de-recognit conting liabil futur gallipr royalti mileston
million
review petx commerci product
gallipr march petx receiv fda approv gallipr
prostaglandin receptor antagonist treatment osteoarthr pain inflamm
dog potenti altern zoeti lead offer rimadyl among other
gallipr licens human pharma compani raqualia
pharma part piprant chemic class uniqu block prostaglandin
receptor key receptor involv pain potenti significantli improv
safeti profil current standard care nsaid zoeti rimadyl
april aratana elanco form collabor agreement provid elanco
global right gallipr exchang million up-front payment mileston
payment certain regulatori manufactur commerci achiev
royalti co-promot fee us intern sale overal deal
arguabl favor less petx particularli given global natur
includ us
specif pursuant agreement elanco pay aratana msd-ldd royalti
sale co-promot fee equal us gross margin msd percentag
net sale europ launch estimate
term mileston petx receiv payment million upon european regulatori
approv inflamm claim gallipr million transfer
manufactur respons third parti commerci basi
gallipr achiev first mileston achiev annual sale
million prior acquisit outstand mileston payment million remain
next mileston trigger million calendar year sale
note disclos april gallipr achiev million revenu
vs million benefit backord push order
initi intern sale expect greater detail intern opportun
confer call may estimate
charl martineau univers toronto figur opportun expand canin pain market
market oppi
nocita petx receiv fda approv nocita august launch product
octob year nocita bupivacain liposom inject suspens
provid hour post-op pain control cranial cruciat ligament knee
surgeri dog technolog in-licens maker
exparel human version product
approxim million canin surgeri perform annual million
pain expens surgeri nocita address acknowledg limit
competit post-op lt pain nich nocita complex administr dose
may limit factor prevent rapid broad-bas adopt note petx
sold nocita directli specialti veterinarian without use distributor product
gener million revenu sale improv sequenti
last eight quarter
entyc petx announc launch entyc canin appetit stimul octob
see note entyc potent select ghrelin agonist
appetit stimul dog receiv fda approv may nearli
million dog diagnos inappet year often first sign
diseas pet malnutrit exacerb underli diseas
product sale somewhat lacklust million petx receiv
order entyc veterinari clinic year re-ord
rate petx recent note need target frequent longer durat use
entyc plan stimul demand focus peer-to-p educ
implement case studi chronic condit
importantli petx also work launch entyc felin though
acknowledg entyc canin use off-label felin entyc cat
receiv technic section complet letter safeti fda februari
enrol pivot studi expect complet
figur gallipr product sale million
figur nocita product sale million
clear
sale
reintroduct
figur entyc product sale million
figur cs veterinari survey prescrib
plan prescrib galliprant/entyc
gallipr launch januari
entyc launch octob
ye prescribe/plan prescrib gallipr
ye prescribe/plan prescrib entyc
compani data credit suiss estim quarter except
weight manag felin
petx receiv technic section complet letter safeti fda
februari expect complet enrol pivot studi
weight manag felin chronic kidney diseas
petx initi regulatori approv process vial size nocita
may make product attract gener veterinari practition
eprociclovir anti-vir treatment felin herp virus-induc
canin osteosarcoma dog age one year
petx launch extend field studi process
recruit patient canin osteosarcoma vaccin two dozen us veterinari
oncolog practic note standpoint revenu sale
timapipr oral antagonist potenti prevent
clinic sign atop dermat at-risk dog
februari petx enter licens agreement askat japanes
life scienc compani develop commerci therapeut candid
potenti pain inflamm dog cat candid sever year
away commerci petx began transfer
manufactur process activ pharmaceut ingredi api earli
pain inflamm
compani mention price
